Oncology News | pharmaphorum

News

Metagenomi prices IPO and NeOnc joins list of hopefuls

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interes

News

Astellas raises Padcev forecasts on bladder cancer data

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m

News

First patient treated with Moderna's PD-1/IDO1 cancer shot

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

News

Global cancer burden study reveals ‘striking inequity’

The World Health Organization (WHO) has said that the burden of cancer on societies around the world is growing at an alarming rate, with a 77% increase in new cases expec

News

AbbVie’s Tepkinly backed by NICE for DLBCL patients

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an

Metagenomi prices IPO and NeOnc joins list of hopefuls

Astellas raises Padcev forecasts on bladder cancer data

First patient treated with Moderna's PD-1/IDO1 cancer shot

FDA sets date for Adaptimmune’s sarcoma drug verdict

Global cancer burden study reveals ‘striking inequity’

AbbVie’s Tepkinly backed by NICE for DLBCL patients

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks